Clinical trials: Illness, Chronic
Chronic Myeloid Leukemia (CML)
Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network
The primary objective of the study is to assess the impact of the organizational model of the hematology center on the quality of life of patients with CML estimated through standardized tools (EORTC QLQ-30, CML24) and through…
- Trial name
- NCT07165535
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- University of Milano Bicocca
Chronic Myelogenous Leukemia
Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+
It is an open-label, randomized, double blind, placebo-controlled parallel-group, multi-center study to evaluate the efficacy and safety of Compound realgar formula Realgar-Indigo naturalis Tablet combined with Imatinib will be…
- Trial name
- NCT01755325
- Testing
- Compound realgar natural indigo Tablet
- Where
- 13 sites in China
- Volunteers
- 680 people
- Sponsor
- Junmin Li
Critical Limb Ischemia
Safety and Efficacy of Autologous Bone Marrow Mononuclear Cells in Patients With Severe Critical Limb Ischemia
The purpose of this study is to evaluate the safety and efficacy of the concentrated autologous bone marrow derived stem cells for the treatment of Critical Limb Ischemia patients.
- Trial name
- NCT01472289
- Testing
- Autologous Bone Marrow Mononuclear cells (BMMNCs)
- Where
- India
- Volunteers
- 17 people
- Sponsor
- TotipotentSC Scientific Product Pvt. Ltd.
Chronic Obstructive Pulmonary Disease
Helium-Hyperoxia and 6MWT Distance in COPD
We assessed the effect of altering inspired gas on the 6MWT distance in COPD. We hypothesized that HeO2 would improve walking distance and reduce shortness of breath compared to both RA and O2, and potentially improve quality of…
- Trial name
- NCT00394225
- Testing
- Oxygen, Helium
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- University of Saskatchewan
Breast Cancer, Leukemia
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00003425
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kentucky
Chronic Hepatitis C
A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-791325 in subjects with chronic hepatitis C infection
- Trial name
- NCT00664625
- Testing
- BMS-791325
- Where
- 6 sites in United States, Argentina
- Volunteers
- 24 people
- Sponsor
- Bristol-Myers Squibb
Myeloproliferative Neoplasm
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
There are 5 parts to this study for which the primary objectives are to evaluate safety, tolerability, and pharmacokinetics (PK) of navitoclax when administered alone (Part 1) or when administered in combination with ruxolitinib…
- Trial name
- NCT04041050
- Testing
- Navitoclax, Ruxolitinib, Celecoxib
- Where
- 42 sites in United States, Belgium and 12 more
- Volunteers
- 85 people
- Sponsor
- AbbVie
Chronic Obstructive Pulmonary Disease Moderate, Chronic Obstructive Pulmonary Disease Severe
Effect of NMES on Quadriceps Muscle Strength and Endurance in Patients With COPD
Chronic Obstructive Pulmonary Disease (COPD) is a respiratory condition that results in a mixture of small airway disease and parenchymal destruction, changes that are characteristic of emphysema.
- Conditions
- Chronic Obstructive Pulmonary Disease Moderate, Chronic Obstructive Pulmonary Disease Severe, Acute Exacerbation of COPD
- Trial name
- NMES (NCT05539547)
- Testing
- Neuromuscular Electrical Nerve Stimulation, Usual Physiotherapy treatment (Chest Physiotherapy and mobility)
- Volunteers
- 140 people
- Sponsor
- Randall Debattista
Asthma (Part 1), COPD (Part 2)
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
This is a phase I, randomised, placebo-controlled 2-part study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8871 delivered by inhalation, in asthmatic and chronic obstructive pulmonary disease…
- Trial name
- NCT02573155
- Testing
- Dose 1, AZD8871 50 μg (Part 1), Dose 2, AZD8871 100 μg (Part 1), Dose 3, AZD8871 300 μg (Part 1)
- Where
- 2 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease, Pulmonary Embolism
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
The purpose of this study is to show that the use of low volume iso-osmolar non-ionic radio contrast medium (30 cc) in a thoracic CT Scanning procedure in a selected group of patients with chronic kidney disease (CKD) will avoid…
- Conditions
- Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis, Pulmonary Cancer
- Trial name
- NCT02476526
- Testing
- Low Volume iso-osmolar non-ionic radio contrast medium, Acetylcysteine Inhalation, Sodium Bicarbonate Solution
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Progressive Multiple Sclerosis
A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Primary Objective: To assess the safety and tolerability of GZ402668 after ascending single intravenous (IV) and subcutaneous (SC) doses in men and women with progressive multiple sclerosis.
- Trial name
- NCT02282826
- Testing
- GZ402668, acyclovir
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Kidney Disease
Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing
A randomized, cross-over, open-label study will be conducted to evaluate the equivalency, safety and tolerability of sevelamer once per day dosing, given with the largest meal, compared with standard three times per day dosing…
- Trial name
- NCT00324376
- Testing
- Sevelamer hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genzyme, a Sanofi Company
Teaching Healthy Cooking Skills to Parents and Their Preschool Children
Cooking HEalthy and Facilitating Early Childhood Development: CHEF-ED Study
This study aims to test a new online program we developed for parents and their preschool children, called CHEF-ED. CHEF-ED focuses on healthy cooking, parental feeding practices, and involving children in home food preparation.
- Trial name
- CHEF-ED (NCT06940817)
- Testing
- CHEF-ED + Food Delivery, Food Delivery Only
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Chronic Myeloid Leukemia
Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia
Fludarabine, cyclophosphamide, and rituximab (FCR) is the gold treatment for fit and young patients with Chronic Lymphoid Leukemia (CLL).
- Trial name
- VeRitAs (NCT03455517)
- Testing
- Venetoclax, Rituximab
- Where
- 31 sites in Italy
- Volunteers
- 77 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Kidney Transplant, Familial Hypercholesterolaemia
Cardiovascular Risk in Children With Chronic Conditions Study
Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels.
- Conditions
- Kidney Transplant, Familial Hypercholesterolaemia, Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM)
- Trial name
- CR3C (NCT07086989)
- Where
- 3 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Semmelweis University
Kidney Disease, Chronic
Impact of Reducing the Dialysate Flow Rate in Chronic Hemodialysis on Dialysis Quality and Environmental Impact on Water Consumption
In France, 60,000 patients are receiving renal replacement therapy via dialysis in 2022, 90% of whom are on hemodialysis. This technique is based on the principle of exchange across a membrane between the patient's blood and the…
- Trial name
- ReDeDia (NCT07718568)
- Testing
- Dialysate flow at 400mL/min, Dialysate flow at 500mL/min
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Pulmonary Disease, Chronic Obstructive
Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients
This study will be the first administration of CCI15106 capsules for inhalation to humans. The primary objective of the study is to investigate the safety and tolerability of single and repeat escalating doses of CCI15106 in…
- Trial name
- NCT03243760
- Testing
- CCI15106 7.5 mg capsule
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease, Diabetes
Diabetes CKD Lifestyle Technology Study
The purpose of this study is to pilot test an mHealth technology-supported behavioral intervention designed to engage patients with diabetes and concurrent chronic kidney disease (CKD) in multiple behaviors which aim to reduce…
- Conditions
- Chronic Kidney Disease, Diabetes, Obesity
- Trial name
- NCT02266823
- Testing
- Social Cognitive Theory
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- NYU Langone Health
Chronic Kidney Disease
The Valid of GFR in Chronic Kidney Disease Patients
Study was cancel due to principle investigator had been resigned
- Trial name
- NCT04610996
- Volunteers
- healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Pulmonary Disease, Chronic Obstructive
Japan Long-term Safety for Tiotropium Plus Olodaterol
The primary objective of this study is to assess the safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC and olodaterol (delivered by the RESPIMAT Inhaler) in Japanese patients with Chronic…
- Trial name
- NCT01536262
- Testing
- Tiotropium + Olodaterol, Respimat, Olodaterol
- Where
- 24 sites in Japan
- Volunteers
- 122 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.